{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:55:18Z","timestamp":1789181718544,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bjoms.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bjoms.2019.09.023","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T15:50:25Z","timestamp":1571586625000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-\u03b1) inhibitors: a systematic review"],"prefix":"10.1016","volume":"58","author":[{"given":"R.","family":"Sacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Leeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Moraschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"de Almeida Barros Mour\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Akintola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjoms.2019.09.023_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int J Cell Biol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1126\/science.3856324","article-title":"Molecular cloning of the complementary DNA for human tumor necrosis factor","volume":"228","author":"Wang","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/313803a0","article-title":"Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor","volume":"313","author":"Shirai","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1385\/MB:31:3:239","article-title":"Tumor necrosis factor as a pharmacological target","volume":"31","author":"Ghezzi","year":"2005","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF \u2014 a primary mediator of the host response","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.sbi.2004.03.003","article-title":"Tumor necrosis factor family ligand-receptor binding","volume":"14","author":"Zhang","year":"2004","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0040","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"24","author":"Koo","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0050","unstructured":"World Health Organization. Expert Committee on Biological Standardization: Geneva, 19\u201323 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from URL: https:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (last accessed 25 September 2019)."},{"key":"10.1016\/j.bjoms.2019.09.023_bib0055","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2174\/0929867322666150429111804","article-title":"An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis","volume":"22","author":"Brezinski","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0060","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF03325637","article-title":"Treatment of psoriasis and psoriatic arthritis","volume":"27","author":"Papoutsaki","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0070","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0075","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors \u2014 state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0080","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.joen.2014.01.035","article-title":"Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report","volume":"40","author":"Alsalleeh","year":"2014","journal-title":"J Endod"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/adj.12235","article-title":"Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis","volume":"60","author":"Horie","year":"2015","journal-title":"Aust Dent J"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0090","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw \u2014 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0095","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0105","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0110","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0115","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0120","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","year":"2011"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0125","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0130","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0135","series-title":"Development of a quality appraisal tool for case series studies using a modified Delphi technique","author":"Moga","year":"2012"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0140","unstructured":"ASPS evidence rating scales. American Society of Plastic Surgeons. Available from URL: https:\/\/www.plasticsurgery.org\/documents\/medical-professionals\/health-policy\/evidence-practice\/ASPS-Rating-Scale-March-2011.pdf (last accessed 26 September 2019)."},{"key":"10.1016\/j.bjoms.2019.09.023_bib0145","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bjoms.2006.06.004","article-title":"Treatment with infliximab: implications in oral surgery? a case report","volume":"45","author":"Ciantar","year":"2007","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0150","article-title":"Adalimumab: another medication related to osteonecrosis of the jaws?","volume":"2016","author":"Cassoni","year":"2016","journal-title":"Case Rep Dent"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ajoms.2016.03.003","article-title":"Mandibular osteomyelitis implicated in infliximab and periapical periodontitis: a case report","volume":"28","author":"Tsuchiya","year":"2016","journal-title":"J Oral Maxillofacial Surg Med Pathol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.joms.2016.07.019","article-title":"Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases","volume":"75","author":"Aghaloo","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0165","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.12659\/AJCR.905355","article-title":"A case of osteonecrosis of the jaw in a patient with Crohn's disease treated with infliximab","volume":"18","author":"Favia","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0170","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.joms.2019.01.033","article-title":"Adalimumab-related dental implant infection","volume":"77","author":"Cillo","year":"2019","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0175","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.120810","article-title":"Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?","volume":"40","author":"Lescaille","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0180","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jcms.2014.09.004","article-title":"Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with anti-TNF therapy. Systematic review","volume":"42","author":"Mar\u00ed","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0185","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.joms.2015.05.022","article-title":"Oral squamous cell carcinoma presenting in a patient receiving adalimumab for rheumatoid arthritis","volume":"73","author":"Beattie","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0190","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/odi.12490","article-title":"BRONJ in patients with rheumatoid arthritis: a multicenter case series","volume":"22","author":"Di Fede","year":"2016","journal-title":"Oral Dis"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0200","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0205","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study","volume":"34","author":"den Broeder","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.21841","article-title":"Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis","volume":"55","author":"Giles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bjoms.2019.09.023_bib0215","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/369565","article-title":"Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy","volume":"2012","author":"da Cunha","year":"2012","journal-title":"Int J Rheumatol"}],"container-title":["British Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435619303936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435619303936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:26:08Z","timestamp":1759418768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0266435619303936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0266435619303936"],"URL":"https:\/\/doi.org\/10.1016\/j.bjoms.2019.09.023","relation":{},"ISSN":["0266-4356"],"issn-type":[{"value":"0266-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-\u03b1) inhibitors: a systematic review","name":"articletitle","label":"Article Title"},{"value":"British Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjoms.2019.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons. All rights reserved.","name":"copyright","label":"Copyright"}]}}